ClinicalTrials.gg
RecruitingNCT05139719Updated Apr 24, 2026

A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients

A Phase 2 interventional study of HEC585 dose A and HEC585 dose B in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), sponsored by Sunshine Lake Pharma Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Primary conditionPulmonary FibrosisRegistry: Lung Diseases, InterstitialReclassifiedWhy we changed it
Registry
Lung Diseases, Interstitial — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Fibrosis
Why
  1. The study's listed conditions name Pulmonary Fibrosis, a narrower term within Lung Diseases, Interstitial.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Pulmonary Fibrosis with a site in China — 14 open to participants now, 18 under way, 4 of them phase 3. Pulmonary Fibrosis · China.

Planned enrollment
17th of 30
110 · median 146
Started
2023
with 8 others
Phase 2
8 of 40
2 open now
Primary completion
2026-12
later than 9 of 17 live
Registered
16th of 40
by date

Among the 40 studies in Pulmonary Fibrosis with a site in China, this one is the 17th largest by planned enrollment of the 30 interventional ones that give a count, is one of 9 that started in 2023, is one of 8 in phase 2, reaches primary completion later than 9 of the 17 other live ones, and was the 16th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

14 of the 40 studies in Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

The main goal of this phase llb study is to compare the efficacy and safety of two doses of HEC585 tablets with placebo which is a look-alike substance that contains no active drug in patients with progressive fibrosing interstitial lung diseases. This study is divided into two stages, i.e. main study stage with 24 weeks treatment duration followed by up to 96 weeks treatment extended study stage.

03

Conditions studied

  • Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)

Browse trials for

04

In context

Pulmonary Fibrosis Reclassified

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

This study's planned enrollment of 110 is above the median of 59 across 212 interventional studies indexed under Pulmonary Fibrosis.

Browse Pulmonary Fibrosis studies →

Lead sponsor

Sunshine Lake Pharma Co., Ltd. is the lead sponsor of 83 studies on the registry; 13 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Pulmonary Fibrosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases, Interstitial. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteer to participate and sign the ICF.
  2. Male or female patients' age ≥ 18 years when signing the ICF.
  3. Patients with known or unknown etiology (except IPF) and clear pulmonary fibrosis on chest CT have undergone conventional clinical treatment (assessed by the investigator, including follow-up observation) for ≥ 3 months. At least two of the following criteria occurring within 12 months before screening without alternative explanation (such as infection, heart failure, etc.):

    i) Worsening respiratory symptoms like cough, shortness of breath. ii) Physiological evidence of disease progression (either of the following):

    1. absolute FVC (% of predicted) decline ≥ 5%.
    2. absolute DLco[ corrected] (% of predicted) decline ≥ 10%. iii) Radiological evidence of disease progression (one or more of the following):

    <!-- -->

    1. Increased extent or severity of traction bronchiectasis and bronchiolectasis.
    2. New ground-glass opacity with traction bronchiectasis.
    3. New fine reticulation.
    4. Increased extent or increased coarseness of reticular abnormality.
    5. New or increased honeycombing.
    6. Increased lobar volume loss.
  4. Fibrosing lung disease on HRCT, defined as reticular abnormality with traction bronchiectasis with or without honeycombing, with disease extent of >10% as confirmed by central readers.
  5. For patients with underlying connective tissue disease (CTD) should be in the stable status which is defined by no initiation of new therapy, treatment dose adjustment or withdrawal of therapy within 12 weeks prior to randomization.
  6. /FVC ≥ 0.7 before using bronchodilators.
  7. %FVC ≥ 45% predicted.
  8. Carbon Monoxide Diffusion Capacity (DLCO) corrected for Haemoglobin (Hb) ≥ 30% and ≤ 80% predicted of normal.
  9. Fertile female or male subjects agreed and promised to take effective measures from signing the ICF till 30 days after last administration.
  10. Subjects are willing and able to comply with the protocol requirements and attend visits assessed by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of Idiopathic Pulmonary Fibrosis (IPF).
  2. Lung with other abnormalities which the investigator assess to have an effect on the results of study.
  3. Significant Pulmonary Arterial Hypertension (PAH), such as meeting the following: Previous clinical or echocardiographic evidence of significant right heart failure, History of right heart catheterization showing a cardiac index ≤ 2 L/min/m², or PAH requiring parenteral therapy with epoprostenol/treprostinil.
  4. Major extrapulmonary physiological or pathological restriction (e.g. chest wall abnormality, large pleural effusion).
  5. Expected to receive lung transplantation during the study.
  6. Expected survival time is less than 6 months.
  7. History of malignant tumors within 5 years (except for localized cancers such as basal cell carcinoma and carcinoma in situ of cervix).
  8. Thyroid dysfunction that the investigator assessed to be clinically significant and needed to be treated.
  9. History of unstable or worsening heart disease during the 6 months prior to screening, including but not limited to the following:

    1. Unstable cardiac angina,
    2. Acute Myocardial infarction,
    3. Congestive heart failure (need to be treated in hospital or III/IV),
    4. Uncontrolled Severe Arrhythmias.
  10. >1.2 × , or ALT > 1.5 × ULN.
  11. \< 50 mL/min.
  12. (HIV) or treponema pallidum antibody is positive.
  13. Uncontrolled virus infection or virus infection.
  14. Use of any of the following medications for the treatment of Interstitial Lung Disease (ILD) or influence the effect or safety of drug:

    1. Strong inducers or strong inhibitors of within 4 weeks before randomization.
    2. Azathioprine (AZA), cyclosporine, MMF ( > 1.5 g/d or equivalent dose), tripterygium glycosides , hydroxychloroquine, tacrolimus, prednisone > 15mg/day or equivalent systemic therapy, and the combination of OCS+AZA+NAC within 4 weeks before randomization.
    3. Cyclophosphamide within 8 weeks before randomization.
    4. Combination of ≤ 15mg/day or equivalent systemic glucocorticoid therapy with ≤ 1.5 g/d or equivalent dose MMF within 12 weeks before randomization.
    5. Pirfenidone or nintedanib within 1 months before screening.
    6. Rituximab, Adalimumab, Secukinumab, Infliximab, Tocilizumab, Certolizumab, Golimumab, Tofacitinib, Baricitinib, Etanercept, Abatacept within 6 months before randomization.
  15. Subjects cannot complete the PFT、6MWT,or questionnaires.
  16. Allergic to any component of HEC585 Tablets.
  17. Participated in other clinical study and received the last dose within 3 months before screening.
  18. Pregnant or breastfeeding.
  19. History of smoking (≥ 10 cigarettes/day) within 3 months before screening or are unwilling to quit smoking during the study.
  20. History of alcohol or drug abuse within 6 months before the screening.
  21. Any condition that, in the opinion of the investigator, would compromise the safety or compliance of the subject, or prevent the subject from completing the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    HEC585 tables does A

    Drug: HEC585 dose A

  • Experimental
    HEC585 tables does B

    Drug: HEC585 dose B

  • Placebo comparator
    placebo

    Placebo once daily up to 24 weeks in main stage; HEC585 dose A once daily up to 96 weeks in extended stage

    Drug: HEC585 dose A · Drug: Placebo

Interventions

  • DrugHEC585 dose A

    taking HEC585 dose A orally once daily, up to 24 weeks in main stage (if applicable); up to 96 weeks in extended stage

  • DrugHEC585 dose B

    taking HEC585 dose B orally once daily, up to 24 weeks in main stage; up to 96 weeks in extended stage

  • DrugPlacebo

    taking Placebo orally once daily, up to 24 weeks in main stage

07

What researchers measure

Primary outcomes

  1. Change from Baseline to Week 24 in FVC (mL) compared with placebo

    change in FVC (mL), measured using Spirometer, from baseline to week 24

    Time frame: 24 Weeks

Secondary outcomes

  1. Change from Baseline to Week 12 in FVC (mL) compared with placebo

    change in FVC (mL), measured using Spirometer, from baseline to week 12

    Time frame: 12 Weeks

  2. Proportion of subjects with the decline from baseline in FVC (% predicted) > 10%

    The proportion of subjects whose %FVC decline from baseline by more than 10% in each treatment group at week 24

    Time frame: 24 Weeks

  3. Proportion of subjects with the decline from baseline in FVC (% predicted) > 5%

    The proportion of subjects whose %FVC decline from baseline by more than 5% in each treatment group at week 24

    Time frame: 24 Weeks

  4. Changes of DLco (Hb correction)

    Time frame: 12 Weeks, 24 Weeks

  5. Changes of 6MWT results

    Time frame: 12 Weeks, 24 Weeks

  6. Changes of St George' s Respiratory Questionnaire (SGRQ)

    The higher the score, the more serious the impact on life

    Time frame: 12 Weeks, 24 Weeks

  7. Changes of The University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ)

    Scores range from 0 to 120. The higher the score, the more severe the difficulty in breathing

    Time frame: 12 Weeks, 24 Weeks

  8. Changes of Leicester coughing questionnaire scores

    Scores range from 3 to 21. The lower the score, the greater the impact of cough on quality of life

    Time frame: 12 Weeks, 24 Weeks

  9. Changes of HRCT

    Time frame: 24 Weeks

  10. Time to first acute ILD exacerbation or death

    the time duration from randomization to first acute ILD exacerbation or death whichever occurs first

    Time frame: 24 Weeks

  11. Proportion of subjects with death caused by any reason(s)

    Time frame: 24 Weeks

  12. Proportion of subjects with death caused by the respiratory reason

    Time frame: 24 Weeks

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.

Of 33 phase 2 interventional studies under Pulmonary Fibrosis, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 75. This study's planned 46 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2021
First posted
Dec 1, 2021
StartActual
Feb 15, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05139719
Responsible party
Sponsor
First posted
Dec 1, 2021
Start date
Feb 15, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 24, 2026

Study contacts

HuaPing Dai, Ph.D
Contact
daihuaping@ccmu.edu.cn
010-84206271

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion